Hot Topics in Heart Failure: New Data and Therapies That Are Changing the Treatment Landscape

Released On
December 15, 2020

Expires On
December 14, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Cardiology, Geriatric Medicine, Hospitalist, Primary Care

Topic(s)
Acute Heart Failure, Cardiovascular Disease, Geriatric Medicine, Heart, Heart Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Clinical Care Options, LLC.

This educational activity is supported by an educational grant from Merck.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for cardiologists, hospitalists, internists, and other healthcare providers who treat patients with heart failure.

Program Overview

The goal of this program is to improve the knowledge and competence of cardiologists, internists, hospitalists, and other clinicians on new and emerging treatment strategies to reduce HF-related hospitalization and death.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize new data from PIONEER-HF regarding timing of initiation of patients receiving ARNIs who have experienced acute decompensated HF
  • Describe the expected benefits on SGLT2 inhibitors in patients with HF
  • Summarize clinical trial data regarding investigational treatments for patients with HFrEF

Faculty

FACULTY_NAME

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

FACULTY_NAME

Javed Butler, MD, MPH, MBA

Patrick H. Lehan Chair in Cardiovascular Research
Professor and Chairman, Department of Medicine
Professor of Physiology
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

  • Funds for Research Support: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company.

Javed Butler, MD, MPH, MBA

  • Consulting Fees: Abbott, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Sequana Medical, V-Wave Limited, Vifor
  • Fees for Non-CME/CE Services: AstraZeneca, Boehringer Ingelheim/Lilly, Janssen, Novartis.

Staff

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Instructions for Participation and Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2020, through December 14, 2021:

  1. Register online at http://www.clinicaloptions.com.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Site Viewing Requirements

  • Web browsers: Latest versions of Edge, Internet Explorer, Chrome, Firefox, and Safari
  • Mobile devices: Latest versions of Android and iOS
  • JavaScript Enabled. This website requires JavaScript to be enabled in your browser. To enable JavaScript, click here.
  • Cookie Enabled. This website requires cookies to be enabled in your browser. To enable cookies, click here.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For CME questions please contact: skelley@clinicaloptions.com